About the Company
Julie E. Czerneda (born April 11, 1955) is a Canadian science fiction and fantasy author. She has written many novels, including four Aurora Award for Best Novel winners (In the Company of Others, A Turn of Light, A Play of Shadow, and The Gossamer Mage), and a number of short stories; she has also edited several anthologies. Czerneda is a biologist by education, and has been active in writing and editing non-fiction. She has edited and authored a number of educational books about career guidance and the teaching of science. In 2022, Czerneda was inducted into the Canadian Science Fiction and Fantasy Association Hall of Fame (CSFFA).
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $GOSS News
Gossamer Bio Inc GOSS
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Gossamer Bio Inc (GOSS) Shares Decline Despite Market Challenges
To sum up, Gossamer Bio Inc (GOSS) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that ...
Buy Rating Affirmed on Gossamer Bio with Promising Seralutinib Prospects in PAH Treatment Landscape
Begin your TipRanks Premium journey today. Gossamer Bio (GOSS) Company Description: Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease ...
Gossamer Bio Stock (NASDAQ:GOSS), Quotes and News Summary
Here Are Other Stocks Moving In Monday's Mid-Day Session Shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) fell sharply during Monday’s session after the company and POINT Biopharma announced ...
Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of Directors
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension ...
Gossamer Bio Inc GOSS
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Buy Rating Affirmed on Gossamer Bio with Promising Seralutinib Prospects in PAH Treatment Landscape
Begin your TipRanks Premium journey today. Gossamer Bio (GOSS) Company Description: Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the ...
Gossamer Bio, Inc. (GOSS)
Overall score is calculated based on proprietary scores based on sector averages in key company indicators: fair value, dividends, innovation, hiring, and insider sentiment. Note: if you don't see ...
Gossamer Bio Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
GOSS Gossamer Bio, Inc.
The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.
Loading the latest forecasts...